{
    "root": "b76b79ce-b7dd-4390-b40e-71ae6c477d10",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Dabigatran Etexilate"
    },
    "value": "20250508",
    "ingredients": [
        {
            "name": "DABIGATRAN ETEXILATE MESYLATE",
            "code": "SC7NUW5IIT"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (90000 WAMW)",
            "code": "UKE75GEA7F"
        },
        {
            "name": "CITRIC ACID MONOHYDRATE",
            "code": "2968PHW8QP"
        },
        {
            "name": "POVIDONE K25",
            "code": "K0KQV10C35"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TARTARIC ACID",
            "code": "W4888I119H"
        },
        {
            "name": "HYPROMELLOSE PHTHALATE (24% PHTHALATE, 55 CST)",
            "code": "87Y6436BKR"
        },
        {
            "name": "POLYETHYLENE GLYCOL 600",
            "code": "NL4J9F21N9"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "SODIUM BICARBONATE",
            "code": "8MDF5V39QO"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        }
    ],
    "indications": "dabigatran etexilate capsules direct thrombin inhibitor indicated : reduce risk stroke systemic embolism adult patients non-valvular atrial fibrillation ( 1.1 ) treatment deep venous thrombosis ( dvt ) pulmonary embolism ( pe ) adult patients treated parenteral anticoagulant 5 10 days ( 1.2 ) reduce risk recurrence dvt pe adult patients previously treated ( 1.3 ) prophylaxis dvt pe adult patients undergone hip replacement surgery ( 1.4 ) treatment venous thromboembolic events ( vte ) pediatric patients 8 less 18 years age treated parenteral anticoagulant least 5 days ( 1.5 ) reduce risk recurrence vte pediatric patients 8 less 18 years age previously treated ( 1.6 )",
    "contraindications": "• non-valvular atrial fibrillation adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily ( 2.2 ) patients crcl 15 30 ml/min : 75 mg orally , twice daily ( 2.2 ) • treatment dvt pe adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily 5 10 days parenteral anticoagulation ( 2.2 ) • reduction risk recurrence dvt pe adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily previous treatment ( 2.2 ) • prophylaxis dvt pe following hip replacement surgery adult patients : patients crcl > 30 ml/min : 110 mg orally first day , 220 mg daily ( 2.2 ) treatment pediatric vte : pediatric patients : weight-based , twice daily least 5 days parenteral anticoagulant ( 2.3 ) reduction risk recurrence pediatric vte : pediatric patients : weight-based , twice daily previous treatment ( 2.3 ) • dabigatran etexilate capsules substitutable milligram-to-milligram basis dabigatran etexilate forms • review recommendations converting oral parenteral anticoagulants ( 2.6 , 2.7 ) • temporarily discontinue dabigatran etexilate capsules invasive surgical procedures possible , restart promptly ( 2.8 )",
    "warningsAndPrecautions": "dabigatran etexilate capsules 75 mg capsules light cream opaque cap light cream opaque body imprinted “ dab ” cap “ 75 ” body black ink . capsules supplied packages listed : • ndc 0904-7253-04 blister package containing 30 ( 3 x 10 ) unit-dose capsules • ndc 0904-7253-68 blister package containing 60 ( 6 x 10 ) unit-dose capsules dabigatran etexilate capsules 110 mg capsules light blue opaque body light blue opaque cap imprinted `` 110 `` body `` dab `` cap black ink . capsules supplied packages listed : • ndc 0904-7254-68 blister package containing 60 ( 6 x 10 ) unit-dose capsules dabigatran etexilate capsules 150 mg capsules light navy blue opaque cap light cream opaque body imprinted “ 150 ” body “ dab ” cap black ink . capsules supplied packages listed : • ndc 0904-7255-10 blister package containing 20 ( 2 x 10 ) unit-dose capsules • ndc 0904-7255-68 blister package containing 60 ( 6 x 10 ) unit-dose capsules bottles store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . opened , product must used within 4 months . keep bottle tightly closed . store original package protect moisture . blisters store 20°c 25°c ( 68°f 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) [ usp controlled room temperature ] . store original package protect moisture . keep reach children .",
    "adverseReactions": "dabigatran etexilate capsules contraindicated patients : • active pathological bleeding [ ( 5.2 ) ( 6.1 ) ] • history serious hypersensitivity reaction dabigatran , dabigatran etexilate , one excipients product ( e.g . , anaphylactic reaction anaphylactic shock ) [ ( 6.1 ) ] • mechanical prosthetic heart valve [ ( 5.4 ) ]",
    "indications_original": "Dabigatran Etexilate Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 )",
    "contraindications_original": "• Non-valvular Atrial Fibrillation in Adult Patients: o For patients with CrCl >30 mL/min: 150 mg orally, twice daily ( 2.2 ) o For patients with CrCl 15 to 30 mL/min: 75 mg orally, twice daily ( 2.2 ) • Treatment of DVT  and PE in Adult Patients: o      For patients with CrCl >30 mL/min: 150 mg orally, twice daily after 5 to 10 days of parenteral anticoagulation ( 2.2 ) • Reduction in the Risk of Recurrence   of  DVT  and PE in Adult Patients: o For patients with CrCl >30 mL/min: 150 mg orally, twice daily after previous treatment ( 2.2 ) • Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients: o For patients with CrCl >30 mL/min: 110 mg orally first day, then 220 mg once daily ( 2.2 ) Treatment of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after at least 5 days of parenteral anticoagulant ( 2.3 ) Reduction in the Risk of Recurrence of Pediatric VTE: For pediatric patients: weight-based dosage, twice daily after previous treatment ( 2.3 ) • Dabigatran Etexilate Capsules are NOT substitutable on a milligram-to-milligram basis with other dabigatran etexilate dosage forms • Review recommendations for converting to or from other oral or parenteral anticoagulants ( 2.6 , 2.7 ) • Temporarily discontinue Dabigatran Etexilate Capsules before invasive or surgical procedures when possible, then restart promptly ( 2.8 )",
    "warningsAndPrecautions_original": "Dabigatran Etexilate Capsules 75 mg capsules have a light cream opaque cap and light cream opaque body imprinted with “DAB” on cap and “75” on body in black ink. The capsules are supplied in the packages listed:  • NDC 0904-7253-04 Blister package containing 30 (3 x 10) Unit-dose Capsules • NDC 0904-7253-68 Blister package containing 60 (6 x 10) Unit-dose Capsules Dabigatran Etexilate Capsules 110 mg capsules have a light blue opaque body and light blue opaque cap imprinted with \"110\" on body and \"Dab\" on cap in black ink. The capsules are supplied in the packages listed: • NDC 0904-7254-68 Blister package containing 60 (6 x 10) Unit-dose Capsules Dabigatran Etexilate Capsules 150 mg capsules have a light navy blue opaque cap and light cream opaque body imprinted with “150” on body and “DAB” on cap in black ink. The capsules are supplied in the packages listed:  • NDC 0904-7255-10 Blister package containing 20 (2 x 10) Unit-dose Capsules • NDC 0904-7255-68 Blister package containing 60 (6 x 10) Unit-dose Capsules\n                     \n                     \n                        Bottles \n                     \n                      Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Once opened, the product must be used within 4 months. Keep the bottle tightly closed. Store in the original package to protect from moisture. \n                     \n                     \n                        Blisters\n                     \n                      Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store in the original package to protect from moisture.\n                      Keep out of the reach of children.",
    "adverseReactions_original": "Dabigatran Etexilate Capsules is contraindicated in patients with:  • Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]\n                      • History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions (6.1)] \n                      • Mechanical prosthetic heart valve [see Warnings and Precautions (5.4)]"
}